9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Estimated reading time: < 1 min

Condition: Acinar Cell Carcinoma

Estimated Enrollment: 707

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Overall response rate (ORR),  Incidence of adverse events,  Best response, Clinical benefit rate

Interventions: Biospecimen Collection, Ipilimumab

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: August 31, 2020

Completion Date: August 31, 2021

Last  Posted Date: August 9, 2019

Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

Website Link: https://ClinicalTrials.gov/show/NCT02834013

Was this article helpful?
Dislike 0